Bevacizumab as maintenance therapy in mCRC: Interpreting results of the MOMA trial.
Bevacizumab as maintenance therapy in mCRC: Interpreting results of the MOMA trial.
Oncotarget. 2019 Apr 19;10(29):2791-2792
Authors: Marmorino F, Falcone A, Cremolini C
PMID: 31073370 [PubMed]
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
More News: Avastin | Cancer & Oncology